News

CIMZIA is the first Fc-free biologic of its kind for this patient population.

FDA grants larotrectinib New Drug Application and Priority Review for the treatment of locally advanced or metastatic solid tumors containing an NTRK gene fusion on both adult and pediatric patients.

The use of diethylstilbestrol during pregnancy was associated with 36% higher odds of ADHD among grandchildren.

A growing class of medications, SGLT-2 inhibitors have helped physicians manage otherwise uncontrolled cases of type 2 diabetes.

This podcast series details the ins and outs of managing, preventing, and treating HIV, from the perspective of the faculty and patients of the UNC Institute for Global Health & Infectious Diseases.

By adjusting protein levels that impact an important biological pathway, researchers improve heart function in mice with HD, shedding light on the biology of the disease.

A recent study sheds light on how the bacteria responsible for necrotizing fasciitis invades the body and explores the role Botox might be able to play in stopping these infections.

The youths’ perception of discrimination was related to a higher risk of MDD over the course of 30 days, then at 12 months, and then over the course of their lifetimes.

A recent CDC report shows an association between the increase in HCV infections and the opioid crisis. Because HCV symptoms may not appear for decades, people often go undiagnosed, which delays treatment.

Even when patients are on ART, the use of stimulants can make their disease worse, according to new research.

In an article recently published by the Institute of Cancer Research, genetic testing was indicated to result in life-extending treatment for incurable pediatric brain tumors.

Facial analysis technology can help identify the most characteristic and relevant facial features found in Williams-Beuren syndrome (WBS) in diverse populations.

Burosumab found to improve outcomes in children with x-linked hypophosphatemia in phase 2 study.

The generalized model can work across hospitals.

Daniel de Boer, CEO of ProQR, Rare Disease Report ® discusses the company’s new RNA therapy, QR-313, for the treatment of dystrophic epidermolysis bullosa (DEB).

Delaying gratification in youth may not be as much of a predictor of later life outcomes, contradictory to previous findings.

Benralizumab has shown a greater reduction of eosinophil levels than that of mepolizumab and reslizumab, but whether or not it's a clinically significant finding is not yet told.

By the time of diagnosis, patients often have costly complications involving the liver.

The FDA has approved pegvaliase-pqpz for the treatment of adults with PKU.

According to BioMarin, the therapy is expected to be available in June 2018, with marketing beginning immediately.

The FDA’s decision was made based on a retrospective analysis of 1000 radiograph images that were used to evaluate the independent enactment of the OsteoDetect AI algorithm.

iLLUMINATE trial meets primary endpoint of PFS in patients with previously untreated chronic lymphocytic leukemia compared with chlorambucil plus obinutuzumab.

In a recent study, hematologists were dubbed pivotal in finding and treating Gaucher disease Type 1.

Christopher-Paul Milne, research associate professor, director of research at Tufts CSDD at Tufts University School of Medicine and the analysis conductor of the study, further explains orphan drug development.

This morning, Pfizer announced that its investigational therapy for the treatment of patients with transthyretin (TTR) cardiomyopathy, tafamidis, received Breakthrough Therapy designation from the US FDA.

The supplemental BLA would expand Coagadex’s prescribing information to include prophylactic and pediatric data.

Since its original approval in 2008, more than 8 million patients worldwide have received a XIENCE stent, according to Abbott.

Until her death in April, Tannehill served as the Associate Professor of Education at Robert Morris University in Pittsburgh, PA. This story is about her journey to her AL Amyloidosis diagnosis.

In patients with hematologic malignancy, the polymerase chain reaction or enzyme immunoassay testing modalities may not be accurate for C. difficile diagnosis.

The CANTOS findings have strengthened the relationship between cardiovascular disease and inflammation. Here’s how they are changing the way clinicians understand heart conditions.